Mankind Pharma Ltd.'s consolidated net profit decreased 10% in the quarter ended March, beating analysts' estimates.
The company posted a profit of Rs 425.1 crore in the fourth quarter as compared to Rs 471.6 crore in the year-ago period, according to an exchange filing on Wednesday. Analysts tracked by Bloomberg had estimated a net profit of Rs 366 crore.
Mankind Pharma Q4 FY25 Highlights (Consolidated, YoY)
Revenue up 27.1% to Rs 3,079.37 crore versus Rs 2,422.24 crore (Bloomberg estimate: Rs 3,096 crore).
Ebitda up 17% to Rs 683.19 crore versus Rs 586.30 crore (Bloomberg estimate: Rs 791 crore).
Margin at 22.2% versus 24.2% (Bloomberg estimate: 25.6%).
Net profit down 10% to Rs 425.11 crore versus Rs 471.57 crore. (Bloomberg estimate: Rs 366 crore).
Shares of Mankind Pharma closed 0.75% lower at Rs 2,530 apiece on the NSE, compared to a 0.52% advance in the benchmark Nifty 50.
RECOMMENDED FOR YOU
Torrent Pharma – JB Chemicals Acquisition: What Should JB Chemicals Shareholders Do?
Jun 30, 2025
Nirmal Bang Maintains 'Hold' On Mankind Pharma Shares, Revises Target Price — Here's Why
Jun 12, 2025
Mankind Pharma Q4 Review: Miss On Operating Performance, Dolat Capital Maintains 'Add' But Cuts Target Price
May 22, 2025
Mankind Pharma Q4 Results Preview: Tariff-Related Risks, Potential Margin Pressure In Focus
May 20, 2025
POPULAR